Author
Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.
6 papers
Recent·Most cited
C. Larrue, S. Mouche, P. Angelino, M. Sajot, R. Birsen, F. Vergez, C. Recher, V. Mansat-De Mas, Q. Gu, J. Xu, P. Tsantoulis, J.-E. Sarry, J. Tamburini
The paper identifies ferritinophagy as a therapeutic target in quiescent leukemic stem cells, showing that inhibiting NCOA4 reduces leukemia.
bioRxiv · Dec 18, 2023 · PreprintCancer Biology
E. Griessinger, D. Pereira-Martins, M. Nebout, C. Bosc, E. Saland, E. Boet, A. Sahal, J. Chiche, D. Debayle, L. Fleuriot, M. Pruis, V. De Mas, F. Vergez, C. Recher, G. Huls, , J.-F. Peyron
The paper identifies cold sensitivity as a vulnerability in FAO-supported OxPhos leukemic stem cells, which can be exploited for therapeutic targeting.
bioRxiv · Apr 17, 2023 · PreprintCancer Biology
y. OUNOUGHENE, E. fourgous, Y. Boublik, E. Saland, N. Guiraud, c. recher, s. urbach, P. P. Fort, J.-E. Sarry, d. fesquet, s. roche
This study identifies PEAK3 as an oncogenic pseudo-kinase that uses the SHED module to activate AKT signaling and promote cancer growth.
bioRxiv · Aug 30, 2021 · PreprintCancer Biology
R. Paolillo, M. Boulanger, P. Gatel, L. Gabellier, D. Tempe, R. Hallal, M. De Toledo, J. Moreaux, H. Baik, E. Gueret, C. Recher, J.-E. Sarry, G. Cartron, M. Piechaczyk, G. Bossis
This study identifies NOX2 as a marker of poor prognosis and a contributor to chemoresistance in AML, showing its upregulation in drug-resistant cells and association with adverse outcomes.
bioRxiv · Mar 4, 2021Cancer Biology
C. Bosc, N. Gadaud, A. Bousard, M. Sabatier, G. Cognet, E. Saland, T. Farge, E. Boet, M. Gotanegre, N. Aroua, P.-L. Mouchel, C. Larrue, L. Jarrou, F. Rambow, F. Cabon, , J.-E. Sarry
This study identifies mitochondrial determinants of response and resistance to venetoclax plus cytarabine therapy in AML, showing that OxPHOS is a predictive marker and that targeting ETCI improves outcomes.
bioRxiv · Aug 17, 2020 · PreprintCancer Biology
C. Larrue, N. Guiraud, P.-L. Mouchel, M. Dubois, T. Farge, M. Gotanegre, C. Bosc, E. Saland, M.-L. Travers-Nicolau, M. Sabatier, N. Serhan, A. Sahal, E. Boet, S. Mouche, Q. Heydt, , J.-E. Sarry
The paper identifies the ADM-CALCRL axis as a driver of drug-tolerant AML cells that persist after chemotherapy and proposes it as a therapeutic target to prevent relapse.
bioRxiv · Aug 17, 2020Cancer Biology